DE69916856T2 - Micropartikeln zur verwendung in nadellosen injektion - Google Patents

Micropartikeln zur verwendung in nadellosen injektion Download PDF

Info

Publication number
DE69916856T2
DE69916856T2 DE69916856T DE69916856T DE69916856T2 DE 69916856 T2 DE69916856 T2 DE 69916856T2 DE 69916856 T DE69916856 T DE 69916856T DE 69916856 T DE69916856 T DE 69916856T DE 69916856 T2 DE69916856 T2 DE 69916856T2
Authority
DE
Germany
Prior art keywords
microparticles
needless injection
therapeutic agent
needless
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69916856T
Other languages
English (en)
Other versions
DE69916856D1 (de
Inventor
David Osborne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quadrant Drug Delivery Ltd
Original Assignee
Quadrant Drug Delivery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10838317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69916856(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Quadrant Drug Delivery Ltd filed Critical Quadrant Drug Delivery Ltd
Publication of DE69916856D1 publication Critical patent/DE69916856D1/de
Application granted granted Critical
Publication of DE69916856T2 publication Critical patent/DE69916856T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Glanulating (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Disintegrating Or Milling (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69916856T 1998-09-03 1999-09-03 Micropartikeln zur verwendung in nadellosen injektion Expired - Lifetime DE69916856T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9819272.7A GB9819272D0 (en) 1998-09-03 1998-09-03 Microparticles
PCT/GB1999/002930 WO2000013668A1 (en) 1998-09-03 1999-09-03 Microparticles

Publications (2)

Publication Number Publication Date
DE69916856D1 DE69916856D1 (de) 2004-06-03
DE69916856T2 true DE69916856T2 (de) 2005-04-21

Family

ID=10838317

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69916856T Expired - Lifetime DE69916856T2 (de) 1998-09-03 1999-09-03 Micropartikeln zur verwendung in nadellosen injektion
DE69938201T Expired - Lifetime DE69938201T2 (de) 1998-09-03 1999-09-03 Mikropartikel

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69938201T Expired - Lifetime DE69938201T2 (de) 1998-09-03 1999-09-03 Mikropartikel

Country Status (15)

Country Link
US (3) US20020197325A1 (de)
EP (2) EP1410792B1 (de)
JP (2) JP2002524411A (de)
CN (1) CN1315854A (de)
AT (2) ATE386507T1 (de)
AU (1) AU5640799A (de)
BR (1) BR9913456A (de)
CA (1) CA2342206C (de)
DE (2) DE69916856T2 (de)
DK (1) DK1107737T3 (de)
ES (2) ES2223181T3 (de)
GB (1) GB9819272D0 (de)
IL (1) IL141323A0 (de)
MX (1) MXPA01002323A (de)
WO (1) WO2000013668A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU770235B2 (en) * 1999-03-08 2004-02-19 Powderject Research Limited Delivery of microparticle formulations using needleless syringe device for sustained-release of bioactive compounds
US8771740B2 (en) * 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
DE10045521A1 (de) 2000-03-31 2001-10-04 Roche Diagnostics Gmbh Nukleinsäureamplifikationen
EP1363602A4 (de) * 2001-01-25 2006-01-11 Euro Celtique Sa Lokalanästhetikum und anwendungsverfahren dafür
EP1399132A1 (de) * 2001-06-08 2004-03-24 Powderject Vaccines, Inc. Herstellung von harten und dichten partikeln
CA2464656C (en) 2001-11-01 2013-07-16 Nektar Therapeutics Spray drying methods and compositions thereof
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
CA2532874A1 (en) * 2003-07-22 2005-02-03 Baxter International Inc. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
JP4210231B2 (ja) * 2004-03-25 2009-01-14 株式会社資生堂 皮膚のシワを改善する美容方法及びシワ改善具
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
WO2006103672A2 (en) * 2005-03-31 2006-10-05 Rafael Armament Development Authority Ltd. Spherically shaped substances
CN101277682B (zh) * 2005-07-28 2015-07-29 Isp投资有限公司 无定形依发韦仑及其生产
EP1976486A1 (de) * 2006-01-27 2008-10-08 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Verfahren zur herstellung von porösen mikroteilchen
CN101500616A (zh) 2006-08-04 2009-08-05 巴克斯特国际公司 预防和/或逆转新发作自身免疫糖尿病的基于微球的组合物
DE202006018609U1 (de) * 2006-08-29 2007-05-16 Euro-Celtique S.A. Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
US20080152717A1 (en) * 2006-12-14 2008-06-26 Isp Investments, Inc. Amorphous valsartan and the production thereof
US8613946B2 (en) * 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
EP2125938A2 (de) * 2007-01-26 2009-12-02 Isp Investments Inc. Verfahren zur herstellung einer formulierung für sprühgetrocknete produkte
ITMI20080807A1 (it) 2008-05-05 2009-11-06 Antibioticos Spa Procedimento per la preparazione di tigeciclina in forma amorfa
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8323685B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
CN101732259B (zh) * 2009-12-29 2012-08-29 广东药学院 壳聚糖微米粒及其制备方法和应用
US9135998B2 (en) * 2010-11-09 2015-09-15 Micron Technology, Inc. Sense operation flags in a memory device
EP2898894A1 (de) 2014-01-27 2015-07-29 LTS LOHMANN Therapie-Systeme AG Nano-in-mikro-Teilchen zur intradermalen Verabreichung
US20200353127A1 (en) * 2018-01-10 2020-11-12 G2Gbio, Inc. Collagen peptide-containing polycaprolactone microsphere filler and preparation method therefor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3937668A (en) * 1970-07-15 1976-02-10 Ilse Zolle Method for incorporating substances into protein microspheres
CA1077842A (en) * 1975-10-09 1980-05-20 Minnesota Mining And Manufacturing Company Albumin medicament carrier system
US4247406A (en) * 1979-04-23 1981-01-27 Widder Kenneth J Intravascularly-administrable, magnetically-localizable biodegradable carrier
US4349530A (en) * 1980-12-11 1982-09-14 The Ohio State University Implants, microbeads, microcapsules, preparation thereof and method of administering a biologically-active substance to an animal
US4357254A (en) * 1981-01-12 1982-11-02 Chemical Sciences, Inc. Cleaning composition
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
FR2663224B1 (fr) * 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
ES2107685T3 (es) * 1992-10-16 1997-12-01 Glaxo Group Ltd Composiciones de ranitidina que enmascaran su sabor.
TW360548B (en) * 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
US5899880A (en) * 1994-04-08 1999-05-04 Powderject Research Limited Needleless syringe using supersonic gas flow for particle delivery
ES2131318T3 (es) * 1994-06-15 1999-07-16 Dumex Ltd As Pelets.
IT1274879B (it) * 1994-08-03 1997-07-25 Saitec Srl Apparecchio e metodo per preparare forme farmaceutiche solide a rilascio controllato del principio attivo.
GB9502879D0 (en) * 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
KR100201352B1 (ko) * 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
US5922253A (en) * 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
US6117449A (en) * 1996-03-22 2000-09-12 Bio-Sphere Technology, Inc. Method for inducing a systemic immune response to a hepatitis antigen
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
GB9612629D0 (en) * 1996-06-17 1996-08-21 Oxford Biosciences Ltd Method for providing dense particle compositions for use in transdermal particle delivery

Also Published As

Publication number Publication date
EP1107737B1 (de) 2004-04-28
WO2000013668A1 (en) 2000-03-16
ATE265204T1 (de) 2004-05-15
BR9913456A (pt) 2001-07-24
DE69938201D1 (de) 2008-04-03
ES2301929T3 (es) 2008-07-01
ES2223181T3 (es) 2005-02-16
DE69916856D1 (de) 2004-06-03
EP1410792A8 (de) 2004-12-29
EP1410792B1 (de) 2008-02-20
CA2342206C (en) 2006-12-12
US20020197325A1 (en) 2002-12-26
US20070026081A1 (en) 2007-02-01
JP2006096755A (ja) 2006-04-13
EP1107737A1 (de) 2001-06-20
IL141323A0 (en) 2002-03-10
CA2342206A1 (en) 2000-03-16
ATE386507T1 (de) 2008-03-15
CN1315854A (zh) 2001-10-03
JP2002524411A (ja) 2002-08-06
GB9819272D0 (en) 1998-10-28
US20050002870A1 (en) 2005-01-06
EP1410792A1 (de) 2004-04-21
DK1107737T3 (da) 2004-08-02
DE69938201T2 (de) 2009-02-12
AU5640799A (en) 2000-03-27
MXPA01002323A (es) 2002-05-08

Similar Documents

Publication Publication Date Title
DE69916856T2 (de) Micropartikeln zur verwendung in nadellosen injektion
DE69836514D1 (de) Elektrodenkörper, mit diesem versehener Akkumulator, sowie Herstellung des Elektrodenkörpers und des Akkumulators
BR9910251A (pt) Estimulação hematopoiética
GR3025596T3 (en) Compositions and methods for identifying biologically active molecules.
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
EP1385466A4 (de) Onkolytische virustherapie
WO1999014346A3 (en) SENSE mRNA THERAPY
NO943473D0 (no) "Freezer"-stykke med hudens pH, og fremgangsmåte for dets fremstilling
MX9603925A (es) Combinaciones de anticoagulantes y proteinas activas tromboliticamente, y usos de las mismas.
DE59903994D1 (de) Fibrin-gewebekleber-formulierung und verfahren zu dessen herstellung
HK1048986B (zh) 2'-取代的1，1'-聯苯-2-甲酰胺、它們的製備方法、作為藥物的用途和含有它們的藥物製劑
EP1123414A4 (de) Antisense modulation der expression von integrin alpha 4
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
IT1295751B1 (it) Procedimento per la produzione di protesi dentali fisse in resina, inserti per le stesse e protesi fisse cosi' ottenute
IL139616A0 (en) Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating, diseases caused by deficiencies thereof
ATE271852T1 (de) Verbesserte inhalationspräparate
BR0000698A (pt) 15, 15'-dioxigenases de beta, beta-caroteno
SE0100684D0 (sv) New subject-matter
BG105204A (en) Salts of paroxetine
IT1285158B1 (it) Polipeptidi solubili con l'attivita' di serino-proteasi di ns3 del virus dell'epatite c, e procedimento per la loro preparazione e il
DE3483377D1 (de) Antibiotikum "chloropolysporin", verfahren zur herstellung und dessen therapeutische und veterinaere anwendung.
DE60010230D1 (de) Pharmazeutische zusammensetzung von hydrophob modifizierten hedgehog-proteinen und deren verwendung
HK1027825A1 (en) Use of arylguanidinium xanthogenates as vulcanization accelerators and process for the production thereof.
DK0542869T3 (da) Vævsplasminogenaktivatorvarianter med nedsat udskillelse
IT8803670A0 (it) Procedimento per la realizzazione di granuli, in particolare granuli sferoidali, ed apparecchiatura per l'attuazione di tale metodo

Legal Events

Date Code Title Description
8363 Opposition against the patent